As part of the Seeding Progress and Resources for the Cancer Community: metastatic Breast Cancer Challenge (SPARC MBC Challenge) launched in 2015 by the Union for International Cancer Control (UICC) and Pfizer, 40 cancer organisations in 30 countries have already received SPARC grants to start new projects addressing the needs of metastatic breast cancer patients.
With 10 additional organisations joining the initiative in 2019, 50 cancer organisations will receive a total funding of US$1,250,000. In addition to seed- grants, the SPARC awardees benefit from trainings, best-practice sharing workshops and mentoring. They will also have the opportunity to participate in key global convening cancer events to network and showcase their work. The application process will open at the end of February.
Read the official press release on the launch for SPARC Round 3
The next SPARC call for proposals is now opened until the 15th April 2019. Read the SPARC Application guidelines and apply through the button below:
Pfizer and UICC are working in partnership to offer the Seeding Progress and Resources for the Cancer Community (SPARC) Metastatic Breast Cancer Challenge, a first-of-its-kind initiative aimed at empowering advocacy groups, hospital networks, support groups and other organisations worldwide as they initiate projects supporting metastatic breast cancer patients and helping to reduce the number of women diagnosed at an advanced stage of breast cancer.
More than 1.6 million women are diagnosed with breast cancer each year and this is increasing particularly in low- and middle-income countries where the majority of cases are diagnosed at late stages.
Launched in 2015, the SPARC MBC Challenge addresses the needs of a growing number of MBC patients across the world. 40 not-for-profit organisations worldwide have already benefitted from SPARC grants, which consist of seed-funding, capacity building and convening opportunities to launch and strengthen new projects addressing the needs of MBC patients. Awardees are integrated into the SPARC network of alumni where they can share best practices, learn from others and share resources.
The primary objective of the SPARC programme is to empower and support patients living with advanced breast cancer to lead lives of a higher quality, and to reduce the incidence of de novo advanced disease. An additional objective of the programme is to enable SPARC grantee organisations to increase their capacity, knowledge and visibility through training opportunities, mentorship and peer-to-peer learning with other SPARC grantees.
SPARC grants support projects in three focus areas:
In 2015, breast cancer constitutes 25% of all cancer cases diagnosed around the world. Over the next decade, more than 16 million women will learn that they have breast cancer, and approximately one-third of these women will develop advanced disease (stages III and IV). While global funding for early stage disease has received essential and substantial attention, much fewer resources have been dedicated to advanced breast cancer patients. It is an incurable disease, requiring a robust and individualised response from a given health system, as well as long-term social and psychological resources as patients face complicated decisions, and often face discrimination and a sense of isolation.